Citamax Tablets 50/850 mg
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
MFDS item code 201503230 · Approved 2015.05.27
This product's status changed to Expired on 2025.05.27. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication helps patients with type 2 diabetes to manage their blood sugar more effectively when used in conjunction with diet and exercise. Sitagliptin and metformin work together to help stabilize blood sugar levels. It is therefore suitable for patients who need blood sugar control.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is one 50/500 mg tablet twice daily. The dose may be increased to one 50/1000 mg tablet twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Use This Medicine). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take the patient's blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used, with the following dosage adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who have no other conditions that may increase the risk of lactic acidosis. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment Because this medicine contains metformin, it should not be administered to patients with hepatic impairment (see Precautions for Use, 2. Patients Who Must Not Use This Medicine).
This medication contains sitagliptin and metformin and is used for the treatment of type 2 diabetes. First, a severe allergic reaction may occur during the use of this medication, so if symptoms such as skin rash, itching, or difficulty breathing appear, you should immediately stop taking it and consult a doctor. Additionally, this medication may lead to pancreatitis, which is an inflammation of the pancreas. If you experience symptoms such as abdominal pain, nausea, or vomiting after taking it, you should visit the hospital immediately. Metformin can cause lactic acidosis, which is a rare but very dangerous condition. If you have difficulty breathing, muscle pain, fatigue, or abdominal pain, seek medical attention immediately. This medication should not be taken by patients with impaired kidney function or in states that can affect kidney function, such as severe infections, dehydration, heart failure, or acute myocardial infarction. Also, when undergoing tests that use radiocontrast agents, this medication should be temporarily discontinued and resumed only after confirming normal kidney function post-examination. Women who are pregnant, may become pregnant, or are breastfeeding should not take this medication, nor is it recommended for children under 18 years of age as safety and efficacy have not been established. During treatment, attention is required as the risk of hypoglycemia or lactic acidosis may increase if meal intake is irregular, there is excessive exercise, or if other medications are being taken concurrently. This medication can cause side effects such as diarrhea, nausea, headache, upper respiratory infections, and especially when taken with insulin or sulfonylureas, hypoglycemia symptoms may occur more frequently. Regular monitoring of kidney function and blood tests should be conducted to ensure the safety of this medication, and vitamin B12 deficiency can occur, so periodic checks of blood vitamin B12 levels are recommended. Alcohol consumption may increase the risk of side effects from this medication, so it is safer to avoid drinking during treatment. In case surgery is necessary, this medication should be discontinued 48 hours before the procedure and restarted only after confirming normal recovery of kidney function post-surgery. Finally, it is important to regularly check blood sugar levels and health status during treatment to closely monitor therapeutic effects and the occurrence of side effects.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a sealed container to prevent air and moisture from entering, and it is recommended to keep it at a temperature between 1 to 30 degrees Celsius. Proper storage will help maintain the effectiveness of the medication for a longer time.
Pink oval film-coated tablets
30 tablets/box [10 tablets/PTP X 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.